JP7359785B2 - 二量体及びその使用 - Google Patents

二量体及びその使用 Download PDF

Info

Publication number
JP7359785B2
JP7359785B2 JP2020567251A JP2020567251A JP7359785B2 JP 7359785 B2 JP7359785 B2 JP 7359785B2 JP 2020567251 A JP2020567251 A JP 2020567251A JP 2020567251 A JP2020567251 A JP 2020567251A JP 7359785 B2 JP7359785 B2 JP 7359785B2
Authority
JP
Japan
Prior art keywords
isvd
specific
ctla4
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526377A (ja
JP2021526377A5 (https=
Inventor
ティン シュー
カンピン グオ
ドン ヤン
ピーリン ワン
ユーハオ ジン
シャオシャオ ワン
Original Assignee
江蘇康寧杰瑞生物制薬有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇康寧杰瑞生物制薬有限公司 filed Critical 江蘇康寧杰瑞生物制薬有限公司
Publication of JP2021526377A publication Critical patent/JP2021526377A/ja
Publication of JP2021526377A5 publication Critical patent/JP2021526377A5/ja
Application granted granted Critical
Publication of JP7359785B2 publication Critical patent/JP7359785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020567251A 2018-06-05 2019-06-04 二量体及びその使用 Active JP7359785B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/090012 2018-06-05
CN2018090012 2018-06-05
CN2019086821 2019-05-14
CNPCT/CN2019/086821 2019-05-14
PCT/CN2019/089980 WO2019233413A1 (en) 2018-06-05 2019-06-04 Dimer and use thereof

Publications (3)

Publication Number Publication Date
JP2021526377A JP2021526377A (ja) 2021-10-07
JP2021526377A5 JP2021526377A5 (https=) 2021-11-18
JP7359785B2 true JP7359785B2 (ja) 2023-10-11

Family

ID=68769178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567251A Active JP7359785B2 (ja) 2018-06-05 2019-06-04 二量体及びその使用

Country Status (6)

Country Link
US (2) US12281163B2 (https=)
EP (1) EP3802613A4 (https=)
JP (1) JP7359785B2 (https=)
CN (2) CN112399973B (https=)
TW (1) TWI831789B (https=)
WO (1) WO2019233413A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
US12565531B2 (en) 2019-12-04 2026-03-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
WO2021110107A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
JP2024510111A (ja) * 2021-02-23 2024-03-06 江蘇康寧杰瑞生物制薬有限公司 腫瘍の予防、軽減、又は治療方法
WO2023070160A1 (en) * 2021-10-28 2023-05-04 Monash University Variant ctla4 proteins
WO2025085590A1 (en) * 2023-10-20 2025-04-24 Jecho Laboratories, Inc. Multifunctional pd1 fusion proteins
EP4574165A1 (en) 2023-12-21 2025-06-25 Egle Therapeutics Immunocytokine for cancer treatment
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2017020801A1 (zh) 2015-07-31 2017-02-09 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017123650A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017198212A1 (zh) 2016-05-19 2017-11-23 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
EP2931747B1 (en) 2012-12-11 2020-06-10 Vib Vzw Anti-influenza antibody
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
CN105754990A (zh) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
EP3494130A4 (en) 2016-08-03 2020-01-08 The Feinstein Institute for Medical Research C1Q AND HMGB1 FUSION PROTEINS AND USES THEREOF
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN111051350B (zh) 2017-09-07 2022-11-01 苏州丁孚靶点生物技术有限公司 包含信号调节蛋白α的免疫缀合物
EP3710480A4 (en) 2017-11-17 2021-12-15 Nanjing Legend Biotech Co., Ltd. SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN112399973B (zh) 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
US12565531B2 (en) * 2019-12-04 2026-03-03 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
WO2021110107A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2017020801A1 (zh) 2015-07-31 2017-02-09 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017123650A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017198212A1 (zh) 2016-05-19 2017-11-23 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oncotarget，2017年，Vol. 8, No. 52，P. 90215-90224

Also Published As

Publication number Publication date
US12281163B2 (en) 2025-04-22
CN112399973B (zh) 2022-12-16
CN112399973A (zh) 2021-02-23
US20210246210A1 (en) 2021-08-12
US11634492B2 (en) 2023-04-25
EP3802613A1 (en) 2021-04-14
TW202003588A (zh) 2020-01-16
TWI831789B (zh) 2024-02-11
JP2021526377A (ja) 2021-10-07
WO2019233413A1 (en) 2019-12-12
CN115991787A (zh) 2023-04-21
EP3802613A4 (en) 2022-03-09
US20210095031A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
JP7359785B2 (ja) 二量体及びその使用
JP7184866B2 (ja) Ｐｄ１および／またはｌａｇ３結合性物質
JP7271637B2 (ja) 抗ｐｓｍａ抗体、ｐｓｍａ及びｃｄ３と結合する二重特異性抗原結合分子、ならびにその使用
US11434299B2 (en) Anti-BCMA heavy chain-only antibodies
CN108290951B (zh) 优化抗cd3双特异性抗体和其用途
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
JP2019214591A (ja) 抗ｃｄ３抗体、ｃｄ３及びｃｄ２０に結合する二重特異性抗原結合分子、並びにそれらの使用
EP3642236A1 (en) Anti-bcma heavy chain-only antibodies
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ
JP2023549851A (ja) 葉酸受容体アルファに結合する重鎖抗体
WO2022171080A1 (zh) 抗cd112r抗体及其用途
US20240270840A1 (en) Antibodies against cd112r and uses thereof
CN114174337A (zh) 针对犬ctla-4的犬源化抗体
CA3186099A1 (en) Anti-cldn-18.2 antibody and use thereof
HK40037173B (en) Dimer and use thereof
HK40037173A (en) Dimer and use thereof
HK40095391A (en) Anti-bcma heavy chain-only antibodies
EA051900B1 (ru) Антитела против cd112r и варианты их применения
HK40098230A (zh) 针对cd112r的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230928

R150 Certificate of patent or registration of utility model

Ref document number: 7359785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150